Table 1.
Baseline Characteristics of Patients
| Patient Characteristics, Median (IQR), no. (%) | N=17 |
|---|---|
| Age (years) | 53 (43–78) |
| ECOG performance-status score | |
| 1 | 12 (70.6) |
| 2 | 2 (11.8) |
| 3 | 3 (17.6) |
| Tumor stage | |
| I–II | 8 (47.1) |
| III–IV | 9 (52.9) |
| Tumor grade | |
| 1 | 5 (29.4) |
| 2 | 7 (41.2) |
| 3 | 3 (17.6) |
| Unknown | 2 (11.8) |
| Pathological type | |
| Squamous cell carcinoma | 13 (76.5) |
| Adenocarcinoma | 4 (23.5) |
| Morbid state at enrollment | |
| Persistence | 9 (52.9) |
| Recurrence or metastasis | 7 (41.2) |
| Refractory | 1 (5.9) |
| Cycle number of H101 | |
| 1 | 7 (41.2) |
| ≥2 | 10 (58.8) |
| Therapy method | |
| H101 monotherapy | 8 (47.1) |
| Combination therapy | 9 (52.9) |
| Injection site | |
| Cervix | 11 (64.7) |
| Corpus uteri | 1 (5.9) |
| Vagina | 5 (29.4) |
| Prior radiotherapy | 16 (94.1) |
| Prior systemic chemotherapies (cycles) | |
| ≤4 | 6 (35.3) |
| >4 | 11 (64.7) |